Zobrazeno 1 - 10
of 32
pro vyhledávání: '"David D.L. Bowtell"'
Autor:
Kathleen I. Pishas, Kathryn Alsop, George Au-Yeung, Therese Hoang, Michael Friedlander, Sian Fereday, David D.L. Bowtell, Elizabeth L. Christie, Alison Freimund
BRCA1 and BRCA2 tumor suppressor genes are central components of the homologous recombination (HR) DNA repair pathway, a high-fidelity process required to maintain genome integrity in the presence of DNA damaging agents. Germline or somatic mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee71b7b84deacb5036d4e2a7060c436b
https://doi.org/10.1016/b978-0-12-819840-7.00013-3
https://doi.org/10.1016/b978-0-12-819840-7.00013-3
Autor:
Aline Talhouk, Michael S. Anglesio, Paul D.P. Pharoah, Joshua Millstein, Timothy Budden, Anna deFazio, Jennifer A. Doherty, Gottfried E. Konecny, Sandra Orsulic, Michelle J. Henderson, David D.L. Bowtell, Simon A. Gayther, Peter A. Fasching, Susan J. Ramus, David G. Huntsman, Andrew Berchuck, Georgia Chenevix-Trench, María Josefa Mosteiro García, Alicia Beeghly-Fadiel, Ellen L. Goode
5583Background: Median survival for high-grade serous ovarian cancer (HGSOC) patients is 3-4 years with a wide range of outcomes. Gene expression patterns have been reported to be predictive of out...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac139185bfb7eae3677fd12e3aabcfe7
Autor:
Jonathan Tyrer, Georgia Chenevix-Trench, Jenny Lester, Penelope M. Webb, Jacek Gronwald, Julie M. Cunningham, Usha Menon, Cezary Cybulski, Anna de Fazio, Allan Jensen, Maria P. Intermaggio, Karen Hosking, Donghui Li, Ellen L. Goode, Anna H. Wu, Jennifer Alsop, Celeste Leigh Pearce, Mary Anne Rossing, Thilo Dörk, Chad D. Huff, Jennifer B. Permuth, Estrid Høgdall, Joellen M. Schildkraut, Susanne K. Kjaer, Douglas A. Levine, Anna Jakubowska, Paul D.P. Pharoah, Beth Y. Karlan, Ed Dicks, Stacey J. Winham, Andrew Berchuck, Yao Yu, Jan Lubinski, David D.L. Bowtell, Holly R. Harris, James D. Brenton, Patricia Harrington, Isaac H Y Chan, Ian G. Campbell, Miquel Angel Pujana, Kirsten B. Moysich, Jennifer A. Doherty, Francesmary Modugno, Susan J. Ramus, Natalia Bogdanova, Anna M. Piskorz, Catherine J. Kennedy, Roberta B. Ness, Robert A. Vierkant, Elke Van Oudenhove, Nadia Traficante, Simon A. Gayther, Conxi Lázaro, Honglin Song, Matthias Dürst, Michelle A.T. Hildebrandt, Xifeng Wu, Teodora Goranova, Marjorie J. Riggan, Kunle Odunsi
PurposeThe known EOC susceptibility genes account for less than 50% of the heritable risk of ovarian cancer suggesting other susceptibility genes exist. The aim of this study was to evaluate the contribution to ovarian cancer susceptibility of rare d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79b9af54fa8cd0b6169901244d93206a
Autor:
Xiao-Jun Ma, Emerald Doolittle, Kathleen I. Pishas, Alison Freimund, Niyati Jhaveri, Jessica A. Beach, Wei Wei, Bingqing Zhang, Nidhi Vashistha, Elizabeth L. Christie, David D.L. Bowtell, Kathryn Alsop
Publikováno v:
Clinical Cancer Research. 26:A65-A65
As we strive to prolong patient survival, the advent of targeted therapy for the treatment of ovarian cancer has significantly added to our armamentarium. Unfortunately, both chemotherapy and molecularly targeted PARPi approaches share the overarchin
Autor:
Laura Galletta, Dariush Etemadmoghadam, Martin Köbel, Huei San Leong, Joshy George, David D.L. Bowtell, Susan J. Ramus
Publikováno v:
The Journal of Pathology. 236:272-277
High-grade serous carcinomas (HGSCs) account for approximately 70% of all epithelial ovarian cancers diagnosed. Using microarray gene expression profiling, we previously identified four molecular subtypes of HGSC: C1 (mesenchymal), C2 (immunoreactive
Autor:
Brooke L. Fridley, Dale W. Garsed, Madalene Earp, Melissa C. Larson, Ellen L. Goode, Julie M. Cunningham, David D.L. Bowtell, Chen Wang, Yanina Natanzon, Kimberly R. Kalli, Sebastian M. Armasu, Stacey J. Winham
Publikováno v:
Cancer Informatics
Cancer Informatics, Vol 17 (2018)
Cancer Informatics, Vol 17 (2018)
High-grade serous ovarian cancer (HGSOC) is a complex disease in which initiation and progression have been associated with copy number alterations, epigenetic processes, and, to a lesser extent, germline variation. We hypothesized that, when summari
Autor:
David D.L. Bowtell
Publikováno v:
Nature Reviews Cancer. 10:803-808
Germline mutation in either BRCA1 or BRCA2 is associated with an increased risk of ovarian cancer, particularly the most common invasive histotype - serous carcinoma. In addition, serous ovarian cancers have an unusually high frequency of other molec
Publikováno v:
Clinical Cancer Research. 24:A14-A14
Background: Deleterious TP53 mutations are found in 99% of patients with high-grade serous ovarian cancer (HGSOC). TP53 missense mutations, found in two-thirds of HGSOC tumors, endow the mutant protein with new gain-of-function (GOF) activities leadi
Autor:
Justin Bedo, Adam Kowalczyk, Richard W. Tothill, Evangeline Buela, Fan Shi, Robert Klupacs, Linda Mileshkin, David D.L. Bowtell, Keith Byron, Lisa Paiman
Publikováno v:
Pathology. 47(1)
Accurate identification of the primary tumour in cancer of unknown primary (CUP) is required for effective treatment selection and improved patient outcomes. The aim of this study was to develop and validate a gene expression tumour classifier and in
Publikováno v:
Cancer Research. 77:2787-2787
Epithelial ovarian cancer is a complex disease and patients vary considerably in response to treatment. A subset of patients responds well to endocrine therapy, however hormone receptor positivity does not predict response and there are no biomarkers